TriangleLu-177-DOTATATE (NCT03206060)
Lu-177-DOTATATE trial for Pheochromocytoma (NCT03206060). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged 18–100 with progressive, inoperable pheochromocytoma or paraganglioma, positive somatostatin-receptor imaging, and either SDHx mutations or no known susceptibility mutation. Standard first-line therapy must be unsuitable or declined.
The idea: Lu-177-DOTATATE targets somatostatin receptors to deliver DNA-damaging radiation. Patients receive four intravenous treatments about eight weeks apart, with amino acids for kidney protection.
This phase 2 study plans 130 patients. Frank Lin leads the NCI-sponsored study at the NIH Clinical Center in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.